Compare Stocks: ALT, NUVB, PHVS, and SION

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$3.07 +2.3%	$2.89	$2.56 ▼ $6.44	$597.02M	0.27	4.36 million shs	8.15 million shs
NUVB Nuvation Bio	$6.46 +4.8%	$5.63	$2.18 ▼ $9.75	$2.25B	1.52	5.55 million shs	4.65 million shs
PHVS Pharvaris	$33.87 +5.0%	$32.89	$19.56 ▼ $36.60	$2.22B	-2.31	293,304 shs	250,542 shs
SION Sionna Therapeutics	$49.94 +1.4%	$41.83	$16.48 ▼ $51.73	$2.25B	1.32	396,534 shs	913,070 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	+5.63%	+1.35%	-5.06%	-1.96%	-16.90%
NUVB Nuvation Bio	-2.55%	-7.22%	+8.44%	+27.56%	+177.70%
PHVS Pharvaris	-1.13%	-5.06%	-4.75%	+7.43%	+61.25%
SION Sionna Therapeutics	+4.52%	+8.55%	+11.98%	+20.23%	+191.13%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$3.07 +2.3%	$2.89	$2.56 ▼ $6.44	$597.02M	0.27	4.36 million shs	8.15 million shs
NUVB Nuvation Bio	$6.46 +4.8%	$5.63	$2.18 ▼ $9.75	$2.25B	1.52	5.55 million shs	4.65 million shs
PHVS Pharvaris	$33.87 +5.0%	$32.89	$19.56 ▼ $36.60	$2.22B	-2.31	293,304 shs	250,542 shs
SION Sionna Therapeutics	$49.94 +1.4%	$41.83	$16.48 ▼ $51.73	$2.25B	1.32	396,534 shs	913,070 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	+5.63%	+1.35%	-5.06%	-1.96%	-16.90%
NUVB Nuvation Bio	-2.55%	-7.22%	+8.44%	+27.56%	+177.70%
PHVS Pharvaris	-1.13%	-5.06%	-4.75%	+7.43%	+61.25%
SION Sionna Therapeutics	+4.52%	+8.55%	+11.98%	+20.23%	+191.13%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	2.70	Moderate Buy	$15.71	411.87% Upside
NUVB Nuvation Bio	2.64	Moderate Buy	$12.88	99.46% Upside
PHVS Pharvaris	2.79	Moderate Buy	$50.08	47.87% Upside
SION Sionna Therapeutics	2.85	Moderate Buy	$53.22	6.57% Upside

Current Analyst Ratings Breakdown

Latest ALT, NUVB, PHVS, and SION Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/28/2026	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/27/2026	NUVB Nuvation Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$17.00 ➝ $21.00
7/23/2026	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$11.00
7/22/2026	NUVB Nuvation Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
7/17/2026	NUVB Nuvation Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	PHVS Pharvaris	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	PHVS Pharvaris	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$55.00
7/15/2026	PHVS Pharvaris	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/7/2026	NUVB Nuvation Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$20.00 ➝ $19.00
7/7/2026	NUVB Nuvation Bio	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$12.00 ➝ $13.00
7/6/2026	NUVB Nuvation Bio	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold

(Data available from 8/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$40K	14,925.57	N/A	N/A	$1.99 per share	1.54
NUVB Nuvation Bio	$62.90M	35.73	N/A	N/A	$0.88 per share	7.34
PHVS Pharvaris	N/A	N/A	N/A	N/A	$4.71 per share	N/A
SION Sionna Therapeutics	N/A	N/A	N/A	N/A	$6.88 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$88.09M	-$0.93	N/A	N/A	N/A	-214,860.98%	-42.57%	-35.57%	8/11/2026 (Estimated)
NUVB Nuvation Bio	-$204.63M	-$0.43	N/A	N/A	N/A	-102.06%	-44.10%	-23.80%	8/6/2026 (Estimated)
PHVS Pharvaris	-$198.79M	-$3.18	N/A	N/A	N/A	N/A	-67.56%	-61.13%	8/11/2026 (Estimated)
SION Sionna Therapeutics	-$75.27M	-$1.93	N/A	N/A	N/A	N/A	-27.31%	-25.88%	N/A

Latest ALT, NUVB, PHVS, and SION Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ALT Altimmune	-$0.15	N/A	N/A	N/A	$0.00 million	N/A
8/11/2026	Q2 2026	PHVS Pharvaris	-$0.7467	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	NUVB Nuvation Bio	-$0.1417	N/A	N/A	N/A	$27.03 million	N/A
5/13/2026	Q1 2026	ALT Altimmune	-$0.25	-$0.18	+$0.07	-$0.18	$0.00 million	N/A
5/12/2026	Q1 2026	PHVS Pharvaris	-$0.8219	-$0.70	+$0.1219	-$0.69	N/A	N/A
5/12/2026	Q1 2026	SION Sionna Therapeutics	-$0.52	-$0.60	-$0.08	-$0.60	N/A	N/A
5/4/2026	Q1 2026	NUVB Nuvation Bio	-$0.0280	$0.01	+$0.0380	$0.01	$66.22 million	$83.23 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A
SION Sionna Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	0.12	29.56	29.56
NUVB Nuvation Bio	0.15	7.44	7.24
PHVS Pharvaris	N/A	11.24	11.24
SION Sionna Therapeutics	N/A	22.60	22.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%
NUVB Nuvation Bio	61.67%
PHVS Pharvaris	N/A
SION Sionna Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ALT Altimmune	1.60%
NUVB Nuvation Bio	30.11%
PHVS Pharvaris	N/A
SION Sionna Therapeutics	5.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	50	194.47 million	191.36 million	Optionable
NUVB Nuvation Bio	60	348.20 million	243.36 million	Optionable
PHVS Pharvaris	30	65.41 million	N/A	Not Optionable
SION Sionna Therapeutics	35	45.15 million	42.85 million	N/A

ALT, NUVB, PHVS, and SION Headlines

Recent News About These Companies

Perceptive Advisors LLC Decreases Position in Sionna Therapeutics, Inc. $SION

August 2 at 6:07 AM | marketbeat.com

36,540 Shares in Sionna Therapeutics, Inc. $SION Purchased by Stempoint Capital LP

July 30, 2026 | marketbeat.com

Brokerages Set Sionna Therapeutics, Inc. (NASDAQ:SION) Target Price at $53.22

July 30, 2026 | americanbankingnews.com

Sionna Therapeutics, Inc. $SION Position Decreased by Orbimed Advisors LLC

July 27, 2026 | marketbeat.com

Sionna Therapeutics, Inc. (NASDAQ:SION) Given Consensus Recommendation of "Moderate Buy" by Analysts

July 25, 2026 | marketbeat.com

Sionna Therapeutics (NASDAQ:SION) Stock Price Down 4.5% - What's Next?

July 20, 2026 | marketbeat.com

Jennison Associates LLC Has $58.18 Million Holdings in Sionna Therapeutics, Inc. $SION

July 20, 2026 | marketbeat.com

Sionna Therapeutics (NASDAQ:SION) Hits New 12-Month High - Should You Buy?

July 18, 2026 | marketbeat.com

Sionna Therapeutics (NASDAQ:SION) Trading Up 5.3% - Time to Buy?

July 17, 2026 | marketbeat.com

Sionna Therapeutics

July 13, 2026 | fool.com

Candriam S.C.A. Buys New Position in Sionna Therapeutics, Inc. $SION

July 13, 2026 | marketbeat.com

Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells 85,918 Shares

July 10, 2026 | insidertrades.com

Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells $3,854,281.48 in Stock

July 9, 2026 | marketbeat.com

Sionna Therapeutics (NASDAQ:SION) Director Sells 115,844 Shares

July 3, 2026 | insidertrades.com

Sionna Therapeutics: NBD1 Stabilization Could Redefine Cystic Fibrosis Treatment

June 30, 2026 | seekingalpha.com

Sionna Therapeutics, Inc. Common Stock (SION) Institutional Holdings

June 23, 2026 | nasdaq.com

Sionna Stockholders Reelect Directors, Ratify Deloitte as Auditor

June 18, 2026 | tipranks.com

Sionna Therapeutics, Inc. (SION) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

June 10, 2026 | seekingalpha.com

Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences

May 27, 2026 | globenewswire.com

Stifel Nicolaus Sticks to Their Buy Rating for Sionna Therapeutics, Inc. (SION)

May 26, 2026 | theglobeandmail.com

Freedom Broker downgrades Sionna Therapeutics (SION)

May 21, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ALT, NUVB, PHVS, and SION Company Descriptions

Altimmune NASDAQ:ALT

$3.07 +0.07 (+2.33%)

Closing price 04:00 PM Eastern

Extended Trading

$3.05 -0.02 (-0.65%)

As of 05:14 PM Eastern

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Nuvation Bio NYSE:NUVB

$6.46 +0.30 (+4.79%)

Closing price 03:59 PM Eastern

Extended Trading

$6.46 0.00 (0.00%)

As of 05:12 PM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Pharvaris NASDAQ:PHVS

$33.87 +1.62 (+5.02%)

Closing price 04:00 PM Eastern

Extended Trading

$33.84 -0.02 (-0.07%)

As of 04:46 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

Sionna Therapeutics NASDAQ:SION

$49.94 +0.68 (+1.38%)

Closing price 04:00 PM Eastern

Extended Trading

$49.88 -0.06 (-0.12%)

As of 05:04 PM Eastern

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients. Our goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide-binding domain 1 (“NBD1”). Despite having long been identified as a critical component for proper CFTR function, NBD1 has been considered “undruggable,” and none of the currently approved CF therapies directly stabilizes NBD1. Worldwide revenue for approved CFTR modulators was approximately $10 billion in 2023 and is expected to grow to $15 billion by 2029. Leveraging more than a decade of our co-founders’ research on NBD1, we are advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in the NBD1 domain. Approximately 90% of people with CF carry at least one copy of the F508del genetic mutation. We believe stabilizing NBD1 is central to unlocking dramatic improvements in clinical outcomes and quality of life for CF patients. We have employed biophysical, cell-based and virtual screening campaigns and extensive use of structural biology to guide the optimization of novel small molecule NBD1 stabilizers. We are conducting ongoing Phase 1 trials of our two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (“PK”) profile of single and multiple ascending doses in healthy subjects. These trials are randomized (3:1 active:placebo), doubled-blinded, placebo-controlled and are being conducted in Australia. As of January 14, 2025, five single ascending dose (“SAD”) cohorts and three multiple ascending dose (“MAD”) cohorts of SION-719 have been completed, with over 60 healthy subjects dosed, and six SAD cohorts and three MAD cohorts of SION-451 have been completed, with over 70 healthy subjects dosed. Both SION-719 and SION-451 have been generally well tolerated based on interim Phase 1 clinical data as of the data cutoff date of January 14, 2025. We have established target exposure levels for SION-719 and SION-451 to potentially provide clinically meaningful benefit, if administered as part of a dual combination or as an add-on to the current standard of care (“SOC”), based on our preclinical cystic fibrosis human bronchial epithelial (“CFHBE”) model. In these trials, we have achieved the target concentrations for SION-719 and SION-451 with single and multiple doses. We plan to continue enrolling healthy subjects in additional MAD cohorts. We are also developing a portfolio of complementary CFTR modulators designed to work synergistically with our NBD1 stabilizers to improve CFTR function, as seen in preclinical models. In July 2024, we in-licensed three clinical-stage compounds from AbbVie Global Enterprises Ltd. (“AbbVie”) to expand our portfolio of combination product opportunities, including galicaftor (SION-2222), which targets CFTR’s transmembrane domain 1 (“TMD1”), and has completed Phase 2 clinical trials. In addition, we recently completed a Phase 1 clinical trial evaluating SION-109, which targets CFTR’s intracellular loop 4 (“ICL4”) region. We plan to evaluate multiple NBD1 stabilizer candidates and complementary modulator candidates and select the most promising candidates to advance into later-stage development. Initially, we intend to evaluate the lead NBD1 stabilizer candidate in combination with the current standard of care, Trikafta, in a proof-of-concept trial. In parallel, we will determine the proprietary dual combination that we believe is optimal to advance into a later-stage clinical trial in CF patients. We were incorporated under the laws of the State of Delaware in August 2019 under the name Sling Therapeutics, Inc., and changed our name to Sionna Therapeutics, Inc. in July 2021. Our principal executive offices are located at 21 Hickory Drive, Suite 500, Waltham, MA. We have one subsidiary, Sionna Therapeutics Securities Corporation (f/k/a Sling Therapeutics Securities Corporation), formed in 2020 under the laws of the Commonwealth of Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALT, NUVB, PHVS, and SION Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALT, NUVB, PHVS, and SION Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALT, NUVB, PHVS, and SION Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ALT, NUVB, PHVS, and SION Company Descriptions

Altimmune NASDAQ:ALT

Nuvation Bio NYSE:NUVB

Pharvaris NASDAQ:PHVS

Sionna Therapeutics NASDAQ:SION

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALT, NUVB, PHVS, and SION Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALT, NUVB, PHVS, and SION Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALT, NUVB, PHVS, and SION Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ALT, NUVB, PHVS, and SION Company Descriptions

Altimmune NASDAQ:ALT

Nuvation Bio NYSE:NUVB

Pharvaris NASDAQ:PHVS

Sionna Therapeutics NASDAQ:SION

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools